Stay updated on Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial
Sign up to get notified when there's something new on the Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial page.

Latest updates to the Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page revision label updated from v3.3.1 to v3.3.2, indicating a minor page update. No substantive trial content appears to have changed.SummaryDifference0.1%

- Check21 days agoChange DetectedPublications section updated to clarify that publications are automatically filled from PubMed. Revision tags updated to v3.3.1 (additions) and v3.2.0 (deletions).SummaryDifference0.1%

- Check29 days agoChange DetectedThe notice about government funding and operating status was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check43 days agoChange DetectedNo significant changes detected on the Study Details page for NCT03695510; core sections and information remain the same.SummaryDifference0.4%

- Check71 days agoChange Detected- Updated operating-status notice and new version tag (v3.2.0) added; old version tag (v3.1.0) removed. The page now provides current status guidance and a newer software/document version.SummaryDifference4%

- Check79 days agoChange DetectedUpdated the page from revision v3.0.2 to v3.1.0, signaling a new release version.SummaryDifference0.1%

Stay in the know with updates to Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial page.